Vireo Growth Buys New York Cannabis Facility for $88.5 Million

Transaction Structure and Financing Terms

Vireo financed the $88.5 million purchase through seller notes and a credit facility from Chicago Atlantic Real Estate Finance, avoiding an all-cash close. The structure reflects a pattern in cannabis M&A where traditional bank financing remains unavailable under federal prohibition. Chicago Atlantic, a real estate investment trust specializing in cannabis-secured lending, has deployed over $1.2 billion in the sector since 2019.

The disclosure didn't specify the split between seller financing and third-party debt. Seller financing in cannabis real estate deals typically carries interest rates of 8-12% and terms of 3-5 years, structured to defer tax liability for the seller under IRC §453 installment-sale rules.

New York Market Context and Regulatory Backdrop

New York's adult-use cannabis program, administered by the Office of Cannabis Management (OCM), has issued 463 retail licenses and 127 cultivation licenses as of May 2026. The state's Marijuana Regulation and Taxation Act (MRTA), enacted March 2021, established a vertically integrated licensing structure with separate permits for cultivation, processing, distribution, and retail.

Vireo holds one of New York's original ten medical licenses issued under the 2014 Compassionate Care Act. Those legacy operators were granted first priority for adult-use cultivation and processing licenses under MRTA §68, converting in phases beginning January 2023. The facility acquired in this transaction wasn't identified by name or location in the May 29 disclosure.

Vireo's Operational Footprint and Capital Strategy

Vireo operates vertically integrated cannabis businesses in Minnesota, New York, and Maryland, with total cultivation canopy exceeding 200,000 square feet. The company reported $47.3 million in revenue for fiscal 2025, a 22% increase year-over-year, driven by adult-use sales in Maryland and Minnesota's July 2025 retail launch.

Key operational metrics for Vireo as of Q1 2026:

• 18 dispensaries across three states
• Three cultivation facilities totaling 210,000 sq ft canopy
• Gross margin of 41% in Q1 2026, compressed by IRC §280E disallowances
• Outstanding debt of $63 million as of March 31, 2026

This $88.5 million acquisition represents Vireo's largest single capital deployment since its 2019 acquisition of a Minnesota cultivation campus for $22 million. Financing through Chicago Atlantic and seller notes avoids dilutive equity raises, a priority the company outlined in its Q4 2025 earnings call.

For full background on New York's licensing framework and market dynamics, see the CannIntel topic hub on New York Cannabis Market.

We'll be watching Vireo's Q2 2026 earnings, expected late August, for disclosure of the facility's production capacity and integration timeline. New York cultivation licenses require operators to commence production within 18 months of issuance under 9 NYCRR §128.6.